Klaus A. Dugi
Ingelheim Am Rhein, RP 55218, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
Journal: JACC. CardioOncology
Published: September 10, 2019
The Boehringer Ingelheim employee study (Part 2): 10-year cardiovascular diseases risk estimation.
Journal: Occupational medicine (Oxford, England)
Published: July 09, 2016
Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status.
Journal: The American journal of clinical nutrition
Published: October 26, 2014
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
Journal: Diabetes, obesity & metabolism
Published: June 17, 2014
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: December 23, 2013
Association between a gene variant near ataxia telangiectasia mutated and coronary artery disease in men.
Journal: Diabetes & vascular disease research
Published: November 28, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 07, 2013
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Journal: Drug metabolism and pharmacokinetics
Published: November 15, 2012
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: August 06, 2012
Last Updated: 09/26/2026